menu
    • menu
    [{"orgOrder":0,"company":"GEMoaB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UniCAR-T-CD123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ Inapplicable"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UniCAR-T-CD123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ Inapplicable"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"UniCAR-T-CD123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ Undisclosed"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Intellia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"RevCAR-T 1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GEMoaB \/ Intellia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GEMoaB \/ Intellia Therapeutics"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UniCAR-T-PSMA","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by GEMoaB

    Menu

    GEMoaB

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GEMoaB

                            Germany arrow
                            BioProcess International Europe
                            Not Confirmed

                            GEMoaB

                            Germany arrow
                            BioProcess International Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UniCAR-T-CD123

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company

                            Details : The new company will be headquartered will acquire Cellex’s subsidiary GEMoaB GmbH with established offices and labs in Dresden, Germany. GEMoaB is developing a switchable universal platform UniCAR-T-CD123 to improve the therapeutic window of CAR T-cel...

                            Product Name : UniCAR-T-CD123

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 22, 2021

                            Lead Product(s) : UniCAR-T-CD123

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GEMoaB

                            Germany arrow
                            Breast Cancer
                            Not Confirmed

                            GEMoaB

                            Germany arrow
                            Breast Cancer
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UniCAR-T-CD123

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GEMoaB Announces First Patient Apheresed in a Phase IA Study

                            Details : Apheresed the first patient in a Phase IA study with UniCAR-T-CD123, the lead product candidate from its proprietary UniCAR cellular immunotherapy platform.

                            Product Name : UniCAR-T-CD123

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 03, 2020

                            Lead Product(s) : UniCAR-T-CD123

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GEMoaB

                            Germany arrow
                            BioProcess International Europe
                            Not Confirmed

                            GEMoaB

                            Germany arrow
                            BioProcess International Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RevCAR-T 1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Intellia Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation ...

                            Details : The companies will conduct joint research to combine GEMoaB’s proprietary RevCAR technology platform with Intellia’s proprietary genome editing technologies to discover and develop next-generation allogeneic cellular immunotherapies to treat cancers ...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 20, 2020

                            Lead Product(s) : RevCAR-T 1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Intellia Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GEMoaB

                            Germany arrow
                            BioProcess International Europe
                            Not Confirmed

                            GEMoaB

                            Germany arrow
                            BioProcess International Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UniCAR-T-CD123

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming AACR Meetin...

                            Details : The AACR poster presentations highlight GEMoaB's rapidly switchable universal CAR-T platform, UniCAR. The UniCAR platform promises an improved therapeutic window and increased efficacy and safety over conventional CAR-T therapies in hematological maligna...

                            Product Name : UniCAR-T-CD123

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 15, 2020

                            Lead Product(s) : UniCAR-T-CD123

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GEMoaB

                            Germany arrow
                            BioProcess International Europe
                            Not Confirmed

                            GEMoaB

                            Germany arrow
                            BioProcess International Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UniCAR-T-PSMA

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Initiation of First UniCAR Cellular Immunotherapy Study in Advanced Solid Tumors

                            Details : GEMoaB has apheresed the first patient in a Phase IA study with UniCAR-T-PSMA, the lead solid tumor product candidate from its proprietary UniCAR cellular immunotherapy platform.

                            Product Name : UniCAR-T-PSMA

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 12, 2020

                            Lead Product(s) : UniCAR-T-PSMA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth